Braveheart Bio raised more than $382 million in an initial public offering, one of the larger biotech debuts of the year, to fund a heart drug it licensed from China.

The company priced 21.2 million shares at $18 on August 5, 2026, for total proceeds of about $382.5 million, and trades on the Nasdaq as BRVE.

What the drug class does

Braveheart develops cardiac myosin inhibitors — drugs that reduce excessive heart-muscle contraction in hypertrophic cardiomyopathy (HCM), a condition in which the heart muscle thickens and stiffens.

The mechanism is unusual in cardiology for acting directly on the contractile machinery. Myosin is the motor protein that pulls against actin to generate force in every heartbeat, and in HCM — typically caused by mutations in the genes encoding those proteins — the interaction is excessive. The muscle contracts too forcefully and relaxes incompletely.

Inhibiting myosin reduces the number of motor heads available to engage, dialling contraction back toward normal. It addresses the actual defect rather than compensating for its consequences, which is what distinguishes the class from everything used before it.

Why HCM was previously hard to treat

Conventional therapy relied on beta blockers and calcium channel blockers, borrowed from other cardiac conditions. Both slow the heart and reduce contractility indirectly, and neither targets the underlying overactivity.

Patients with severe obstruction — where thickened muscle impedes blood leaving the heart — often required surgical removal of muscle tissue or a catheter procedure inducing a controlled infarction to shrink it. Effective, invasive, and available at few centres.

A drug that reduces obstruction pharmacologically substitutes for those procedures, which is why the class was significant when it arrived.

The non-obstructive question

Lead candidate BHB-1893 targets both obstructive and non-obstructive HCM, and that second population is the strategically interesting one.

Obstructive disease has a clear mechanical problem and a measurable endpoint: reduce the pressure gradient across the outflow tract and symptoms improve.

In non-obstructive HCM the muscle is thickened and stiff without blocking outflow. Patients still have exercise intolerance, breathlessness and arrhythmia risk, driven by impaired filling rather than obstructed emptying. There is no gradient to reduce and no equally clean endpoint, which is why the established drug in the class has had a harder time demonstrating benefit there.

A drug succeeding in that population would address genuine unmet need. It is also the harder trial.

Licensed from China

BHB-1893 was licensed from China’s Hengrui Pharma and is in Phase 3 testing in China, with global trials planned for late 2026 or early 2027.

The model has become common: a US company licenses Western rights to an asset already advanced by a Chinese developer, paying considerably less than originating the programme would cost and acquiring clinical data already generated.

The residual risk is regulatory. Data from trials conducted entirely in one population raise questions about generalisability, and Western regulators typically expect trials including their own populations — which is what the planned global programme provides.

The competitive position

That puts Braveheart on a collision course with Bristol Myers Squibb’s Camzyos, the established drug in the class.

Entering against an approved incumbent requires a differentiating claim — better efficacy, easier dosing, fewer monitoring requirements, or effect in a population the incumbent does not serve well. The non-obstructive indication is the most plausible candidate.

Monitoring is a real burden with the existing drug: reducing contraction too far causes heart failure, so patients require repeated echocardiography, and prescribing is restricted accordingly. A drug with a wider therapeutic window would be commercially meaningful.

A hot IPO week

Founded only in 2024 and led by CEO Travis Murdoch, Braveheart raised a $185 million Series A less than a year before going public.

Its debut came amid a busy stretch: the 17th drugmaker to go public in 2026, and one of five biotechs pricing IPOs that week for more than $1 billion combined — with median biotech IPO proceeds now around $300 million.

Why HCM is more common than it looks

Hypertrophic cardiomyopathy is often described as rare, and the characterisation is misleading in a way that shapes the commercial opportunity.

Population screening studies estimate it affects roughly one in 500 people, which makes it the most common inherited heart condition. Most of those people are undiagnosed, because many have mild disease and no symptoms, and the condition is typically found incidentally — on an echocardiogram ordered for another reason, or during family screening after a relative is diagnosed.

It is also the leading cause of sudden cardiac death in young athletes, which is how it enters public awareness despite that being a small fraction of cases.

The gap between prevalence and diagnosis means the treated population could grow substantially without any change in disease frequency — and an effective drug class creates the incentive to find those patients. That prospect, more than share taken from an incumbent, is what supports valuations in this space.

That median is high by historical standards and reflects selectivity rather than exuberance: fewer companies reaching public markets, each raising more, typically with a late-stage asset rather than a platform. Business news, not investment advice.